Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer (Q73904210)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

G K Zagars

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

A Pollack

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 September 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

Radiotherapy and Oncology

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

213-221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Prostate-specific antigen and radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Prostate-specific antigen and external beam radiation therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2900123-0

7 January 2021

10.1016/S0167-8140(97)00123-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9380819%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference